Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled study of nebulized BM219 in mild to moderate COVID-19
ChiCTR2400094206Phase 2Completed
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Dec 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BM219 in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by Shenzhen Third People's Hospital. Primary endpoint: Mean change from baseline in viral load in nasopharyngeal swabs within 5 days after treatment. Started Dec 2024; status: completed.
02
Drugs
BM219
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2400094206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094206.